Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. e274 Journal of Hypertension Vol 34, e-Supplement 2, September 2016 Conclusions: The available low quality evidence does not confirm or rule out a substantive difference in benefits or harms between fixed combination and free combination of anti-hypertensive regimen in the management of patients with HTN. Well designed RCTs with a long duration of follow-up and assessment of morbidity and mortality outcomes are needed. PP.26.03 ANTIHYPERTENSIVE EFFICACY OF INDAPAMIDE SR/AMLODIPINE IN HYPERTENSIVE PATIENTS AGED 65 YEARS AND ABOVE: A SUBANALYSIS OF THE 1-YEAR NESTOR STUDY O. Hanon. Hôpital Broca, Paris, FRANCE Objective: The SPRINT study recently demonstrated that lowering systolic blood pressure is particularly beneficial in reducing cardiovascular outcomes in older patients, with guidelines recommending diuretics and calcium channel blockers (CCBs) to treat systolic hypertension in this age group. The objective of this sub- analysis of the NESTOR study was to evaluate the long-term antihypertensive efficacy and safety of indapamide SR/amlodipine in patients aged 65 years and above, over a period of 1 year. Design and method: The NESTOR study included 570 hypertensive (aged 35–80 years, systolic blood pressure [SBP] 140–180 and diastolic blood pressure [DBP] < 110 mmHg), diabetic patients with microalbuminuria, 187 of whom were aged 65 years and above. Antihypertensive therapy was stopped before inclusion and indapamide SR 1.5 mg or enalapril 10 mg administered. If target BP (< 140/90 mmHg) was not achieved at 6 weeks, amlodipine 5 mg was added with uptitration to 10 mg if needed. Follow-up period was 52 weeks. Results: At 52 weeks in 107 patients aged 65 years and above receiving dual ther- apy, SBP/DBP decreased significantly (P < 0.001) from baseline by 30 ± 12/14 ± 9 mmHg with indapamide SR/amlodipine (n = 53) vs 22 ± 16/11 ± 9 mmHg with enalapril/amlodipine (n = 54). There was a significantly greater SBP reduc- tion of 6.2 ± 2.7 mmHg (P = 0.022, adjusted on baseline) with indapamide SR/ amlodipine vs enalapril/amlodipine, a larger difference than that seen in all ages on bitherapy (4.1 ± 1.5 mmHg; P = 0.006). Moreover, BP response rate (< 140/90 mmHg or decrease of 20 mmHg in SBP or 10 mmHg in DBP) in patients aged 65 years and above was greater with indapamide SR/amlodipine (88%) than with enalapril/amlodipine (75%). Indapamide SR and amlodipine were associated with a good safety profile. Three patients in each group discontinued treatment. Conclusions: This analysis indicates that a thiazide-like diuretic/CCB combina- tion (indapamide SR/amlodipine) more effectively lowers SBP than an angioten- sin-converting enzyme inhibitor/CCB combination in these hypertensive patients aged 65 years and above, whilst maintaining a good safety profile. PP.26.04 THE STATUS OF VASOREACTIVITY AND CYTOKINES LEVELS OF PATIENTS WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION V. Paramonov, T. Martynyuk, V. Masenko, I. Chazova. Russian Cardiology Research and Production Complex, Institute of Clinical Cardiology, Moscow, RUSSIA Objective: to assess serum cytokines levels in patients with idiopathic pulmonary ar- terial hypertension (IPAH) depending on the result of acute vasoreactivity test (AVT). Design and method: In the study we included 61 IPAH patients (mean age 32,4 ± 3,2 years). Patients were divided into two groups depending on pulmonary artery vasodila- tor reactivity. In all patients were investigated by serum cytokines levels. Results were compared with control group, 10 healthy volunteers served of control group. Results: In all IPAH patients the levels of IL–1 were not different and were within normal range (p > 0,05) (Table 1). But at one-third of patients the levels of IL–1 were higher than in the control group. In both groups the level of IL-6 TNF, MIP1, sVCAM was significantly higher as compared to control levels. A high level of IL-6 evidence about the formation of an noadequate response organism on injury or inflammation. Intensity of inflammation and endothelial dysfunction and their interaction, noting the existence of a significant positive cor- relation between IL-6 and ET-1 (r = 0,421; p < 0,05). High levels of IL-6 TNFa and MIP1a indicate the presence of inflammation at all stages of development IPAH. IL-8 levels was significantly higher in nonresponder group and pointed to a more pronounced inflammatory reactions sharpness. The differences between the groups of responders and nonresponders confirms a significant correlation between IL-8 and NT-proANP (r = 0,342; p < 0,05), NT- proBNP (r = 0,428; p < 0,05), and NA (r = 0,468; p < 0,05). In all IPAH patients the level of IL-10 was higher than control values. Only in nonresponder group the level of INFg was lower than in the control group. The marker of vascular injury s ICAM was significantly higher than in the control group and the maximum con- centration observed in patients without reserve vasoreactivity. Conclusions: The levels of inflammatory cytokines were significantly increased in the nonresponder group in compare with responder group. The most elevated levels of inflammatory mediator were IL-8 and s ICAM. PP.26.05 BLOOD PRESSURE LOWERING IN INTERMEDIATE RISK PEOPLE WITHOUT VASCULAR DISEASE P. Lopez-Jaramillo 1 , S. Yusuf 2 , E. Lonn 2 , J. Bosch 2 . 1 FOSCAL-UDES, Bucara- manga, COLOMBIA, 2 PHRI-McMaster University, Hamilton, CANADA, On behalf of the Hope 3 investigators Objective: Observational studies in people without cardiovascular (CV) disease show a strong, graded association between blood pressure (BP) above 115/75 mmHg and CV risk. Most BP lowering trials included people with established CV disease, diabetes, renal disease and/or hypertension with end organ damage or in the absence of these conditions those with systolic BP above 160 mmHg. However, most CV events in populations arise from persons without these major risk factor and the role of BP lowering drugs among them is uncertain. Design and method: HOPE-3 was a double-blind randomized placebo-controlled trial with a 2-by-2 factorial design which evaluated BP lowering with candesartan/ hydrochlorothiazide 16/12.5 mg/day, cholesterol lowering with rosuvastatin 10